Loading…
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | $-48M | $-46M | $-38M | -101.0% | -13.2% | - |
| 2024 | $1M | $-48M | $-45M | $-38M | -54.8% | 40.0% | - |
| 2023 | $0M | $-45M | $-41M | $-31M | -59.4% | 26.4% | - |
| 2022 | $0M | $-40M | $-39M | $-35M | -36.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.39 | 0.49 | 0.68 | 0.59 |
| Operating Expense | 40.29 | 45.90 | 49.33 | 49.55 |
| Operating Income | -39.90 | -45.41 | -48.65 | -48.96 |
| EBITDA | -39.67 | -45.01 | -47.71 | -48.06 |
| EBIT | -39.90 | -45.41 | -48.65 | -48.96 |
| Pretax Income | -38.70 | -41.44 | -45.43 | -45.85 |
| Net Income | -38.70 | -41.44 | -45.43 | -45.85 |
| Net Income Common Stockholders | -38.73 | -41.47 | -45.45 | -45.88 |
| Total Expenses | 40.29 | 45.90 | 49.33 | 49.55 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 1.58 | 4.07 | 3.26 | 3.10 |
| Research And Development | 27.11 | 32.86 | 36.85 | 35.33 |
| Selling General And Administration | 13.18 | 13.04 | 12.48 | 14.22 |
| Normalized EBITDA | -39.67 | -45.01 | -47.71 | -48.06 |
| Normalized Income | -38.70 | -41.44 | -45.43 | -45.85 |
| Basic EPS | -0.89 | -0.93 | -0.95 | -0.69 |
| Diluted EPS | -0.89 | -0.93 | -0.95 | -0.69 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -38.70 | -41.44 | -45.43 | -45.85 |
| Reconciled Depreciation | 0.24 | 0.40 | 0.94 | 0.90 |
| Net Interest Income | 1.58 | 4.07 | 3.26 | 3.10 |
| Net Income From Continuing And Discontinued Operation | -38.70 | -41.44 | -45.43 | -45.85 |
| Total Operating Income As Reported | -39.90 | -45.41 | -48.65 | -48.96 |
| Diluted Average Shares | 43.60 | 44.68 | 47.65 | 66.84 |
| Basic Average Shares | 43.60 | 44.68 | 47.65 | 66.84 |
| Diluted NI Availto Com Stockholders | -38.73 | -41.47 | -45.45 | -45.88 |
| Preferred Stock Dividends | 0.02 | 0.02 | 0.02 | 0.03 |
| Net Income Including Noncontrolling Interests | -38.70 | -41.44 | -45.43 | -45.85 |
| Net Income Continuous Operations | -38.70 | -41.44 | -45.43 | -45.85 |
| Other Income Expense | -0.38 | -0.10 | -0.04 | 0.01 |
| Other Non Operating Income Expenses | -0.38 | -0.10 | -0.04 | 0.01 |
| Gain On Sale Of Security | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 1.58 | 4.07 | 3.26 | 3.10 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 1.58 | 4.07 | 3.26 | 3.10 |
| General And Administrative Expense | 13.18 | 13.04 | 12.48 | 14.22 |
| Other Gand A | 6.83 | 6.28 | 6.10 | 6.93 |
| Salaries And Wages | 6.36 | 6.76 | 6.39 | 7.29 |
| Operating Revenue | 0.39 | 0.49 | 0.68 | 0.59 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Cardiff Oncology, Inc.this co. | CRDF | $111M | - | 2.44 | -101.0% | -1.10 |
| AVITA Medical, Inc. | RCEL | $130M | - | -7.76 | 291.8% | -3.91 |
| The Joint Corp. | JYNT | $127M | - | 8.33 | 19.3% | 140.09 |
| Nano-X Imaging Ltd. | NNOX | $119M | - | 0.85 | -28.3% | -1.41 |
| Neuronetics, Inc. | STIM | $118M | - |
| 5.25 |
| -148.6% |
| -6.65 |
| OptimizeRx Corporation | OPRX | $115M | 22.74 | 0.90 | 4.0% | 7.20 |
| Aardvark Therapeutics, Inc. | AARD | $114M | - | 1.07 | -54.0% | -0.07 |
| Definitive Healthcare Corp. | DH | $99M | - | 0.35 | -36.7% | 5.27 |
| Health Catalyst, Inc. | HCAT | $93M | - | 0.37 | -72.4% | -32.70 |
| Peer Median | - | 22.74 | 0.87 | -32.5% | -0.74 | |